Anti-HAV IgM test System, Material No. 11820591160 Product Usage: The Roche Elecsys Anti-HAV IgM immunoassay is used for the in vitro qualitative detection of IgM antibodies to hepatitis A virus (anti-HAV IgM) in human serum and plasma (potassium EDTA, lithium or sodium heparin, sodium citrate). The assay is intended for use as an aid in the laboratory diagnosis of an acute or recently acquired hepatitis A virus infection. Assay results, in conjunction with other laboratory results and clinical information, may be used to provide presumptive evidence of infection with hepatitis A virus in persons with signs and symptoms of hepatitis and in persons at risk for hepatitis A infection. The electrochemiluminescence immunoassay ECLIA is intended for use on Elecsys and cobas e immunoassay analyzers.
Recall
- Recall Number
- Z-0784-2019
- Event Number
- 81823
- Firm
- Roche Diagnostics Corporation
- FEI Number
- 1823260
- Product Code
- LOL
- Status
- Terminated
- Root Cause
- Software Design Change
- Initiated
- December 17, 2018
- Terminated
- April 10, 2020
- Address
- 9115 Hague Rd, Indianapolis, IN, 46256-1025
Description
Anti-HAV IgM test System, Material No. 11820591160 Product Usage: The Roche Elecsys Anti-HAV IgM immunoassay is used for the in vitro qualitative detection of IgM antibodies to hepatitis A virus (anti-HAV IgM) in human serum and plasma (potassium EDTA, lithium or sodium heparin, sodium citrate). The assay is intended for use as an aid in the laboratory diagnosis of an acute or recently acquired hepatitis A virus infection. Assay results, in conjunction with other laboratory results and clinical information, may be used to provide presumptive evidence of infection with hepatitis A virus in persons with signs and symptoms of hepatitis and in persons at risk for hepatitis A infection. The electrochemiluminescence immunoassay ECLIA is intended for use on Elecsys and cobas e immunoassay analyzers.
Potential for erroneous result messages for the Anti-HAV IgM assay when run on the cobas e 602 module. Discrepant result reporting may result.
Roche issued URGENT MEDICAL DEVICE CORRECTION notices and Fax Forms dated 12/17/2018 to customers via UPS courier service. **Actions to be Taken by Customers/Users Currently Using APP-file Version 04.10 - 101** 1. If your LIS host stores the interpretation and COI information for Anti-HAV IgM, all COI results in the gray zone of 0.90 1.10 should be reviewed. Implement the following action for all gray zone results: If discrepant interpretation of results is suspected, re-testing may be advisable in concordance with the recommendations in the assay method sheet and relevant clinical information. 2. Review the APP-file version downloaded for the Anti-HAV IgM application. The most current APP-file version is (05.30 - 402). Download this version of the APP-file for the Anti-HAV IgM assay. You can determine the APP-file version for Anti-HAV IgM currently installed on your cobas e 602 module by going to Utility > Application > Select Anti-HAV IgM test > Analyze tab, bottom right corner of the screen. **Actions Required** - Follow the instructions provided in the Actions to be Taken by Customers/Users Currently Using APP-file Version 04.10 - 101 - Confirm your cobas e 602 module is using APP-file 05.30 - 402. If it is not, immediately update to APP-file 05.30 - 402. - Complete all sections of the fax form (TP-00518) and fax it to 1-855-207-2758 or email it to [email protected]. - File the Urgent Medical Device Correction for future use. Customers with questions please contact the Roche Support Network Customer Support Center, 24 hours a day, seven days a week at 1-800-428-2336
US Nationwide Distribution
70,639 units